HOME / Notice / News / EN
MOU Signing Ceremony Held at Kosin University Gospel Hospital on February 9 (Mon) Joint Advancement in Clinical Research for NK Cell Combination Therapy Targeting Hepatocellular Carcinoma "We Will Accelerate the Realization of Precision Medicine Based on Advanced Regenerative Medical Data" Kosin Univ...
Anticipates Securing Leading Position in Early Diagnosis and Preventive Healthcare Market for Cancer, Dementia, and Other Intractable Diseases Global health tech company Molecular You (MYCo) and NK cell therapy research biotech NKCL Bio Group Co., Ltd. (NKCL) signed a Memorandum of Understanding (MOU...
Spurring Growth as a Domestic Biotech Company Entering the Global Market with NK Cell Automated Incubators NKCL Bio Group (hereinafter referred to as NKCL) announced that it has successfully developed a multi-person (currently up to 16-person) NK cell automated incubator ‘RK-NKTM ACS-II (hereinafter...
Potential for Growth in the Domestic Cell Therapy Market through the Application of Negative Regulation The Ministry of SMEs and Startups announced that on the 21st, it held the "Global Innovation Zone Launch Ceremony" at the Lotte Hotel in Jung-gu, Seoul, with representatives from local governments,...
[ NKCL participates as an anchor company in the Chungbuk Advanced Regenerative Bio Global Innovation Special Zone project ] In establishing a business plan for "Designation of Chungbuk Advanced Regenerative Bio Global Innovation Special Zone" announced last December, on January 19th, hosted by the Ch...